[{"id":"1eb4bfe6-a419-4cd5-9ec6-57d058690b45","acronym":"","url":"https://clinicaltrials.gov/study/NCT01813539","created_at":"2021-01-18T08:03:00.872Z","updated_at":"2024-07-02T16:35:40.457Z","phase":"Phase 1/2","brief_title":"A Study of ARGX-110 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT01813539","lead_sponsor":"OncoVerity, Inc.","biomarkers":" CD70 • CD27","pipe":"","alterations":" ","tags":["CD70 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 02/27/2013","start_date":" 02/27/2013","primary_txt":" Primary completion: 07/10/2020","primary_completion_date":" 07/10/2020","study_txt":" Completion: 07/10/2020","study_completion_date":" 07/10/2020","last_update_posted":"2023-08-09"},{"id":"b7b91d43-2908-4714-880d-0a8d2ca7e7e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030612","created_at":"2021-01-18T14:55:03.502Z","updated_at":"2024-07-02T16:35:40.566Z","phase":"Phase 1/2","brief_title":"A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)","source_id_and_acronym":"NCT03030612","lead_sponsor":"OncoVerity, Inc.","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2023-08-09"},{"id":"eff23d5a-07ca-4bd0-b111-e2ee2ef96220","acronym":"","url":"https://clinicaltrials.gov/study/NCT05842707","created_at":"2023-05-06T15:04:02.816Z","updated_at":"2024-07-02T16:35:48.974Z","phase":"Phase 1/2","brief_title":"Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05842707","lead_sponsor":"Aibin Liang，MD，Ph.D.","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dualCAR-NK19/70"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/18/2023","start_date":" 01/18/2023","primary_txt":" Primary completion: 01/18/2028","primary_completion_date":" 01/18/2028","study_txt":" Completion: 01/18/2029","study_completion_date":" 01/18/2029","last_update_posted":"2023-05-04"},{"id":"72825679-0a90-44dd-8f03-cc33bf0d6f85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05667155","created_at":"2022-12-28T16:01:39.436Z","updated_at":"2024-07-02T16:35:56.379Z","phase":"Phase 1","brief_title":"Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05667155","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD19 expression • CD20 negative","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dualCAR-NK19/70"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-02-06"},{"id":"2be3bc28-b41c-488c-9d96-7369def4b45c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05549557","created_at":"2022-09-22T15:56:27.450Z","updated_at":"2024-07-02T16:36:03.609Z","phase":"Phase 1","brief_title":"IMM40H Phase I Dose Escalation and Expansion","source_id_and_acronym":"NCT05549557","lead_sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMM40H"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-09-22"},{"id":"24c276d5-e174-42f2-ae14-0f6a5076d5fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02759250","created_at":"2021-01-18T13:31:50.817Z","updated_at":"2024-07-02T16:37:08.106Z","phase":"Phase 1","brief_title":"A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)","source_id_and_acronym":"NCT02759250","lead_sponsor":"argenx","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 04/25/2018","primary_completion_date":" 04/25/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-08-08"}]